Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

Background MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests the agent may have mechanisms of action that are independe...

Full description

Bibliographic Details
Main Authors: Tolaney, Sara M., Tan, Sally, Guo, Hao, Barry, William, Van Allen, Eliezer, Wagle, Nikhil, Brock, Jane, Larrabee, Katherine, Paweletz, Cloud, Ivanova, Elena, Janne, Pasi, Overmoyer, Beth, Wright, John J., Shapiro, Geoffrey I., Winer, Eric P., Krop, Ian E.
Format: Online
Language:English
Published: Springer US 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608248/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608248/

Similar Items